|Articles|November 9, 2017

Elligo Health Research and PatientLink Partnership Brings New Opportunities for Physicians and Their Patients

Austin, Texas, Nov. 9, 2017 (Business Wire)-Elligo Health Research, a clinical research infrastructure provider that brings together sponsors, physicians, patients, and CROs to improve clinical trial access and efficiency, is now connecting physicians and patients to treatment options through a new partnership with PatientLink Enterprises, an innovative medical patient data collection and enrollment software development company.

To benefit its customers who are ready to bring clinical studies to their practice, PatientLink is recommending Elligo’s Goes DirectTM approach. The relationship connects physicians who are interested in research with the resources and infrastructure needed to make it possible.

“Introducing select clients to Elligo has allowed us to further fulfill our mission of connecting people to people-first patients to physicians with our electronic health record (EHR) solutions and now physicians to research with Elligo,” said Debi Willis, CEO and Founder of PatientLink. “We are grateful to play a role in engaging physicians and patients in the research that will help uncover ways to live better and longer.”

“We are delighted to be advancing the care PatientLink’s physicians offer to their patients,” said Keith Fern, Chief Commercial Officer at Elligo. “This opportunity will allow us to increase patient access to cutting edge clinical research by putting it in the hands of even more physicians. This is a win for everyone-for patients, for clinicians, and for trial sponsors.”

 

About Elligo

Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology, and medical device products and therapies. Elligo Goes DirectTM with an approach that uses electronic health records and other health data to identify real-world pateints and physicians for participation in clinical studies. Elligo supports health care providers by providing personnel, procedures, technology, and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About PatientLink

PatientLink’s core goal is to improve health and improve patient centered care, by providing multiple ways to collect and share important information between patients and their care givers. PatientLink supplies health organizations with customized software to gather their specific data needs in the day-to-day care for patients. And because every patient is unique and important, PatientLink offers multiple modes for patients to share their information from home or from the office. PatientLink works with many health care organizations, EHR vendors, universities, and government entities to enable the best patient and provider experience in data sharing. Earlier this year, PatientLink won first place in the ONC’s prestigious 2017 Consumer Health Data Aggregator Challenge. 

CONTACT:

Lea Studer

SCORR Marketing

402-366-1752

[email protected] 


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.